Positron emission tomographic imaging of angiogenesis and vascular function.

2.50
Hdl Handle:
http://hdl.handle.net/10541/79036
Title:
Positron emission tomographic imaging of angiogenesis and vascular function.
Authors:
Laking, George R; Price, Patricia M
Abstract:
Surrogate markers of clinical outcome are important in anticancer drug research, since clinical criteria of response develop only slowly and may be confounded by other processes than drug effect. The need for surrogate outcome markers is especially great with newer agents that may act by tumour stabilization as opposed to shrinkage. Neoplastic angiogenesis is associated with a number of detectable changes at molecular and microcirculatory levels. Therefore, direct study of angiogenic molecular biology and tumour circulation before during and after treatment may offer useful surrogate markers for vascular-targeted therapies. The main advantage of radiotracer imaging with positron emission tomography (PET) is its functional specificity. This article will review two main areas: (a) the methodology behind PET imaging of tumour blood supply with 15O-oxygen labelled compounds; and (b) newer tracers in development as markers of angiogenetic biology.
Affiliation:
Cancer Research UK PET Oncology Group, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Citation:
Positron emission tomographic imaging of angiogenesis and vascular function. 2003, 76 Spec No 1:S50-9 Br J Radiol
Journal:
The British Journal of Radiology
Issue Date:
2003
URI:
http://hdl.handle.net/10541/79036
DOI:
10.1259/bjr/30399077
PubMed ID:
15456714
Type:
Article
Language:
en
ISSN:
0007-1285
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLaking, George R-
dc.contributor.authorPrice, Patricia M-
dc.date.accessioned2009-08-28T08:47:04Z-
dc.date.available2009-08-28T08:47:04Z-
dc.date.issued2003-
dc.identifier.citationPositron emission tomographic imaging of angiogenesis and vascular function. 2003, 76 Spec No 1:S50-9 Br J Radiolen
dc.identifier.issn0007-1285-
dc.identifier.pmid15456714-
dc.identifier.doi10.1259/bjr/30399077-
dc.identifier.urihttp://hdl.handle.net/10541/79036-
dc.description.abstractSurrogate markers of clinical outcome are important in anticancer drug research, since clinical criteria of response develop only slowly and may be confounded by other processes than drug effect. The need for surrogate outcome markers is especially great with newer agents that may act by tumour stabilization as opposed to shrinkage. Neoplastic angiogenesis is associated with a number of detectable changes at molecular and microcirculatory levels. Therefore, direct study of angiogenic molecular biology and tumour circulation before during and after treatment may offer useful surrogate markers for vascular-targeted therapies. The main advantage of radiotracer imaging with positron emission tomography (PET) is its functional specificity. This article will review two main areas: (a) the methodology behind PET imaging of tumour blood supply with 15O-oxygen labelled compounds; and (b) newer tracers in development as markers of angiogenetic biology.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshCell Hypoxia-
dc.subject.meshHumans-
dc.subject.meshIntegrins-
dc.subject.meshNeoplasms-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshOxygen Radioisotopes-
dc.subject.meshPositron-Emission Tomography-
dc.subject.meshTissue Inhibitor of Metalloproteinases-
dc.subject.meshVascular Endothelial Growth Factor A-
dc.titlePositron emission tomographic imaging of angiogenesis and vascular function.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK PET Oncology Group, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.en
dc.identifier.journalThe British Journal of Radiologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.